• TechCrunch
• CrunchBase
• More
  • TechCrunch UK
  • TechCrunch France
  • TechCrunch Japan

EnzymeRx

edit

EnzymeRx! a private, clinical stage biotechnology company developing uricase-PEG 20 for the treatment of resistant and refractory gout and related indications in which hyperuricemia plays a causative role. Our patented formulation of pegylated uricase is designed to have a long half life as well as reduced immunogenicity.

Milestones

edit

• 
  EnzymeRx added John Bomalaski as Chief Medical Officer.
  Posted 6/5/09 at 1:58am
• 
  EnzymeRx added Tony Fiorino as President and CEO.
  Posted 6/5/09 at 1:58am
• 
  EnzymeRx received $14M in Unattributed funding. (5/28/08)
  Posted 6/5/09 at 1:58am via enzymerx.com

Videos

Screenshots

edit

Above: Homepage
Uploaded: 6/5/09

Sources

1. EnzymeRx Announces Receipt of $14 million Capital Investment and Acquisition of Pegylated Uricase (enzymerx.com) [edit]